On July, 18 Q BioMed Inc. (QBIO) EPS Estimated At $-0.29

June 27, 2018 - By Margaret Staats

Q BioMed Inc. (OTCMKTS:QBIO) Corporate Logo

On July, 18 Q BioMed Inc. (OTCMKTS:QBIO)’s earnings report is expected by WallStreet, Zacks reports. Analysts predict 0.00 % diference or $-0.29 from the $-0.29 EPS from 2017. Last quarter $-0.17 EPS was reported. Analysts predicts 70.59 % negative EPS growth this quarter. The stock increased 0.29% or $0.01 during the last trading session, hitting $3.42.Q BioMed Inc. has volume of 16,791 shares. Since June 27, 2017 QBIO has 0.00% and is . The stock underperformed the S&P500 by 12.57%.

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies.The firm is worth $47.79 million. The firm offers Strontium Chloride SR89, a radiopharmaceutical agent for the treatment of pain associated with metastatic bone cancer.Currently it has negative earnings. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.